Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase i dose-escalation study

Journal of Clinical Oncology

Volumn 36, Issue 4, 2018, Pages 391-398

  Callahan, Margaret K ^a   Kluger, Harriet ^b   Postow, Michael A ^a   Segal, Neil H ^a   Lesokhin, Alexander ^a   Atkins, Michael B ^c   Kirkwood, John M ^d   Krishnan, Suba ^e   Bhore, Rafia ^e   Horak, Christine ^e   Wolchok, Jedd D ^a   Sznol, Mario ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; IPILIMUMAB; NIVOLUMAB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; CANCER SURVIVAL; CHILL; COLITIS; CONFERENCE PAPER; COUGHING; DEATH; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FLATULENCE; FOLLOW UP; HUMAN; HYPOPHYSITIS; HYPOTHYROIDISM; INOPERABLE CANCER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MULTIPLE ORGAN FAILURE; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VITILIGO; VOMITING; XEROSTOMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; SKIN TUMOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NIVOLUMAB; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85041214863     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.72.2850     Document Type: Conference Paper

References (18)

1. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010
2. Erratum: N Engl J Med 363:1290, 2010
3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
4. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
5. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
6. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
7. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017, 2015
8. Hodi FS, Chesney J, Pavlick AC, et al: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17: 1558-1568, 2016
9. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345-1356, 2017
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Medical Dictionary for Regulatory Activities, version 19.0. https://www.meddra.org/
11. Long GV, Flaherty KT, Stroyakovskiy D, et al: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study. Ann Oncol 28:1631-1639, 2017
12. Long GV, Grob JJ, Nathan P, et al: Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: A pooled analysis of individual patient data from randomised trials. Lancet Oncol 17:1743-1754, 2016
13. Ribas A, Hamid O, Daud A, et al: Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600-1609, 2016
14. Robert C, Ribas A, Hamid O, et al: Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 34, 2016 (suppl 15; abstr 9503)
15. Robert C, Long GV, Schachter J, et al: Longterm outcomes in patients with ipilimumab-näive advanced melanoma in phase 3 KEYNOTE-006 study who completed pembrolizumab treatment. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2-6, 2016 (abstr 9504)
16. Long GV, Atkinson V, Menzies AM, et al: A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2-6, 2016 (abstr 9508)
17. Chiou VL, Burotto M: Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541-3543, 2015
18. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al: Updated results from a phase III trial of nivo-lumab combined with ipilimumab in treatment-näive patients with advanced melanoma (CheckMate 067). American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016 (abstr 9505)